See more : NWTN Inc. (NWTNW) Income Statement Analysis – Financial Results
Complete financial analysis of Helius Medical Technologies, Inc. (HSDT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Helius Medical Technologies, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Arvind Limited (ARVIND.BO) Income Statement Analysis – Financial Results
- Eco Science Solutions, Inc. (ESSI) Income Statement Analysis – Financial Results
- Aura Renewable Acquisitions plc (ARA.L) Income Statement Analysis – Financial Results
- JRC Co.,Ltd. (6224.T) Income Statement Analysis – Financial Results
- Pratiksha Chemicals Limited (PRATIKSH.BO) Income Statement Analysis – Financial Results
Helius Medical Technologies, Inc. (HSDT)
About Helius Medical Technologies, Inc.
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 644.00K | 787.00K | 522.00K | 661.00K | 1.50M | 478.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 583.00K | 463.00K | 298.00K | 388.00K | 846.00K | 0.00 | 0.00 | 0.00 | 171.78K | 0.00 | 0.00 |
| Gross Profit | 61.00K | 324.00K | 224.00K | 273.00K | 650.00K | 478.00K | 0.00 | 0.00 | -171.78K | 0.00 | 0.00 |
| Gross Profit Ratio | 9.47% | 41.17% | 42.91% | 41.30% | 43.45% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.94M | 4.26M | 5.99M | 4.58M | 8.06M | 9.94M | 14.39M | 4.72M | 3.83M | 171.78K | 4.25M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.21M | 8.47M | 5.65M | 4.26M | 895.50K | 4.27M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 774.40K | 0.00 | 0.00 |
| SG&A | 9.27M | 10.64M | 12.18M | 9.71M | 16.52M | 17.21M | 8.47M | 5.65M | 5.04M | 895.50K | 4.27M |
| Other Expenses | 276.00K | 181.00K | 200.00K | 363.00K | 64.00K | 63.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 12.49M | 15.08M | 18.37M | 14.66M | 24.65M | 27.15M | 22.85M | 10.37M | 8.86M | 1.07M | 8.52M |
| Cost & Expenses | 13.07M | 15.55M | 18.66M | 15.05M | 25.49M | 27.15M | 22.85M | 10.37M | 8.86M | 1.07M | 8.52M |
| Interest Income | 0.00 | 834.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 111.00K | 20.07K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 834.00K | 0.00 | 0.00 | 0.00 | 1.95M | 5.17M | 1.67M | 176.49K | 0.00 | 0.00 |
| Depreciation & Amortization | 162.00K | 306.00K | 374.00K | 482.00K | 191.00K | 59.00K | 17.00K | 1.78M | 20.07K | 0.00 | 0.00 |
| EBITDA | -12.11M | -14.50M | -17.82M | -13.90M | -23.93M | -26.62M | -17.67M | -8.60M | -6.83M | -1.07M | -8.52M |
| EBITDA Ratio | -1,879.97% | -2,044.73% | -3,439.08% | -2,132.68% | -2,535.09% | -5,147.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -12.43M | -14.76M | -18.14M | -14.39M | -24.00M | -26.68M | -22.85M | -10.37M | -8.86M | -1.07M | -8.52M |
| Operating Income Ratio | -1,929.81% | -1,875.35% | -3,475.48% | -2,176.40% | -1,604.01% | -5,580.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.58M | 687.00K | 10.00K | 72.00K | 14.22M | -1.95M | -5.17M | -1.67M | 1.98M | 0.00 | 0.00 |
| Income Before Tax | -8.85M | -14.07M | -18.13M | -14.13M | -9.78M | -28.62M | -28.02M | -12.04M | -8.89M | -1.07M | -8.52M |
| Income Before Tax Ratio | -1,374.22% | -1,788.06% | -3,473.56% | -2,137.67% | -653.81% | -5,988.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.51M | -10.00K | -193.00K | -14.12M | 3.96M | 10.34M | 1.67M | -146.62K | 0.00 | -8.52M |
| Net Income | -8.85M | -12.56M | -18.12M | -13.94M | 4.34M | -28.62M | -28.02M | -12.04M | -8.89M | -1.07M | 0.00 |
| Net Income Ratio | -1,374.22% | -1,595.68% | -3,471.65% | -2,108.47% | 290.04% | -5,988.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -14.56 | -46.52 | -368.82 | -581.80 | 288.15 | -2.20K | -2.63K | 0.00 | -27.29 | 0.00 | 0.00 |
| EPS Diluted | -14.56 | -46.52 | -368.82 | -581.80 | 288.15 | -2.20K | -2.63K | 0.00 | -27.29 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 607.89K | 269.94K | 49.14K | 23.96K | 15.06K | 13.02K | 10.65K | 0.00 | 325.99K | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 607.89K | 269.94K | 49.14K | 23.96K | 15.06K | 13.02K | 10.65K | 0.00 | 325.99K | 0.00 | 0.00 |
Helius Medical Technologies, Inc. Expands Stroke Trial at the Medical University of South Carolina
-- Number of subjects increased from 12 to 60 -- -- Portable Neuromodulation Stimulator (PoNS®) will be used to evaluate cranial-nerve non-invasive neuromodulation and dynamic gait/balance in stroke patients -- NEWTOWN, Pa., July 27, 2023 (GLOBE NEWSWIRE) -- Helius Medical...
Helius Medical Technologies Announces DMEPOS Accreditation for PoNS
NEWTOWN, Pa., June 20, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that its Portable Neuromodulation Stimulator...
Helius Medical Technologies to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest
NEWTOWN, Pa., June 14, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Dane Andreeff, President and...
Helius Medical Technologies to Present at LD Micro Invitational XIII 2023
Newtown, Pennsylvania--(Newsfile Corp. - May 25, 2023) - Helius Medical Technologies, Inc. (NASDAQ: HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that Dane Andreeff, President...
Helius to Highlight Innovative PoNS Therapy™ at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting, in Commemoration of World MS Day
NEWTOWN, Pa., May 24, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies (Nasdaq:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for gait deficits, is excited to announce its participation in the prestigious Consortium of Multiple Sclerosis Centers...
Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEWTOWN, Pa., May 19, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT ) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that, effective May 18, 2023, its independent directors approved an equity award under...
Helius Medical Technologies, Inc. Reports First Quarter 2023 Financial Results
-- Company to host call at 4:30pm today -- NEWTOWN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and...
Helius Medical Technologies, Inc. to Release First Quarter 2023 Financial Results on May 11, 2023
NEWTOWN, Pa., May 04, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will...
Helius Medical Technologies to Spotlight Expanded Authorizations for its PoNS Device at 2023 American Academy of Neurology Annual Meeting, Booth 1685
MS, Stroke and mmTBI Cover Broader Set of Indications Across North American Markets MS, Stroke and mmTBI Cover Broader Set of Indications Across North American Markets
7 Sorry Pharma Stocks to Sell in April Before It's Too Late
Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extreme, but investing in pharma stocks can...
Source: https://incomestatements.info
Category: Stock Reports